Ranibizumab (Lucentis®) is a humanized anti-VEGF antibody fragment; FDA approved for the treatment of: neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The gene discussed is VEGFA; the disease is age-related macular degeneration.